复尔康注射液抗肿瘤活性-研究及对血管生成的影响.pdfVIP

growth inhibition rate (antitumor rate) and life extension rate as indicator. ② Established human hepatoma SMMC-7721 cells nude mice xenograft rumor model, nude mice in which tumors don’t grow as well as grow either too slow or too fast were removed 15 days after inoculation, select those nude mice in experiments in which tumors have taken shape and tumor diameter is 3 approximately greater than 50 mm . Intraperitoneal inject 5 days after 2 days’ withdraw every week, lasting for 4 weeks. After measuring tumor diameter and weight 3 times a week, the inhibitory effect of Fu-er-kang Injection on tumor growth of tumor-bearing mice is evaluated by observing variances of tumor volume(TV), relative tumor volume(RTV) and relative tumor proliferation ratio [T/C(%)]. (3) Effect on angiogenesis in vitro: The effects of Fu-er-kang Injection on human microvascular endothelial cell (HMEC) proliferation, migration, and tubule formation were detected by CCK-8 assay, wounding healing assay and tube formation assay. Results: (1) Antitumor activity in vitro: Fu-er-kang Injection significantly inhibited proliferation of K562, SMMC-7721, BeL-7402 cells with IC50 values of (31.751.50), (61.511.58) and (68.397.16) µg/mL respectively. It showed a favourable dose-effect relationship becasue Inhibitory activity strengthened with the increase of concentration. However inhibitory effect on HCT116 and KB was too weak. (2) Antitumor activity in vivo: ① The 6.25,12.5 and 25 mg.kg-1 Fu-er-kang Injection dose group present antitumor rate of 21.50%, 39.10 % and 49.36% respectively on mice hepatoma H22 cells solid tumors(Type S). Compared